Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Former government health officials fear the Trump administration is moving to slow-walk vaccine approvals, including by ...

A new study reveals "serious adverse events" associated with mifepristone, commonly called the "abortion pill," as ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Under emergency use, vaccines can be removed even after a health emergency is considered to be over. Full approval from the FDA means a product can stay on the market even after a health emergency ...

The U.S. Food and Drug Administration this week granted permission for the use of a new cancer drug from China despite ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

The U.S. Food and Drug Administration announced earlier this month that it will be phasing out animal testing for some new ...

Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...